Analyst Price Targets — VYGR
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| March 12, 2025 10:33 am | Yanan Zhu | Wells Fargo | $10.00 | $3.81 | TheFly | Voyager Therapeutics price target lowered to $10 from $12 at Wells Fargo |
| November 13, 2024 3:53 pm | Jay Olson | Oppenheimer | $18.00 | $6.92 | StreetInsider | Oppenheimer Reiterates Outperform Rating on Voyager Therapeutics (VYGR) |
| September 25, 2024 6:53 am | Jack Allen | Robert W. Baird | $18.00 | $6.04 | StreetInsider | Baird Reiterates Outperform Rating on Voyager Therapeutics (VYGR) |
| May 14, 2024 6:47 am | Laura Chico | Wedbush | $8.00 | $8.48 | StreetInsider | Voyager Therapeutics (VYGR) PT Lowered to $8 at Wedbush |
| January 2, 2024 1:08 pm | Jim Birchenough | Wells Fargo | $14.00 | $9.00 | StreetInsider | Wells Fargo Upgrades Voyager Therapeutics (VYGR) to Overweight |
| May 10, 2023 3:18 pm | Joon Lee | Truist Financial | $18.00 | $9.88 | Benzinga | Voyager Therapeutics' Seasoned Management And Leading Adeno-Associated Virus Capsid Platform Impress Bullish Analyst |
Latest News for VYGR
LEXINGTON, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced that the company will participate in the following upcoming investor conferences: Wells Fargo 21st Annual Healthcare Conference: Fireside chat at 3:45 p.m.
Dimensional Fund Advisors LP decreased its position in Voyager Therapeutics, Inc. (NASDAQ: VYGR) by 19.3% in the undefined quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 875,568 shares of the company's stock after selling 208,931 shares during the period. Dimensional Fund Advisors LP owned
- Data presented as Developing Topics poster at AAIC 2026 - LEXINGTON, Mass., July 13, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today presented six-month good laboratory practice (GLP) toxicology data for VY1706, the Company's investigational gene therapy targeting intracellular and extracellular tau…
On the June 30 episode of Mad Money, a 23-year-old caller named Jackson from Iowa asked Jim Cramer about Voyager Therapeutics (NASDAQ:VYGR), a clinical-stage gene therapy company he wanted to hold for the long haul.
LEXINGTON, Mass. , June 29, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced a Developing Topics (late-breaking) poster presentation at the upcoming Alzheimer's Association International Conference (AAIC) taking place in London, July 12-15, 2026.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for VYGR.
U.S. House Trading
No House trades found for VYGR.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.